Want to see JP:190A full AI Analyst Report?
Top Page
Chordia Therapeutics Inc.
(190A)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥70.00
▼(-35.19% Downside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by weak financial performance (zero revenue in 2024–2025, large losses, and heavy cash burn with declining equity), partially offset by the benefit of having no reported debt. Technicals add modest support only from neutral momentum indicators, but the price remains below key moving averages, and valuation is hindered by a negative P/E with no dividend yield provided.
Positive Factors
Debt-free balance sheet
No reported debt limits interest and refinancing risk, giving Chordia greater flexibility to fund clinical development. This is particularly valuable for an R&D-stage biotech whose future financing needs may remain significant before commercialization.
Negative Factors
Persistent pre-revenue losses
The absence of revenue leaves Chordia dependent on financing and successful clinical progress rather than recurring operating income. Continued large losses reduce financial visibility and make the company’s ability to reach commercialization dependent on future development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt limits interest and refinancing risk, giving Chordia greater flexibility to fund clinical development. This is particularly valuable for an R&D-stage biotech whose future financing needs may remain significant before commercialization.
Read all positive factors
Chordia Therapeutics Inc. (190A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.72B
Dividend YieldN/A
Average Volume (3M)565.44K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue GrowthN/A
EPS Growth33.26%
CountryJP
Employees20
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-20.05
Shares Outstanding77,258,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chordia Therapeutics Inc. Business Overview & Revenue Model
Company Description
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of re...
How the Company Makes Money
Chordia Therapeutics’ primary business model is typical of an R&D-stage biotech company: it invests in developing proprietary drug candidates and seeks to monetize them through a combination of (a) upfront payments and milestone payments from lice...
Chordia Therapeutics Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.50B | 0.00 | 800.00M |
| Gross Profit | -797.00K | -1.43B | -4.09M | 2.49B | -3.15M | 0.00 |
| EBITDA | -1.44B | -1.79B | -1.82B | 218.10M | -1.77B | -586.97M |
| Net Income | -1.43B | -1.79B | -1.83B | 223.34M | -1.78B | -527.11M |
Balance Sheet | ||||||
| Total Assets | 2.59B | 2.68B | 4.63B | 4.91B | 4.50B | 2.27B |
| Cash, Cash Equivalents and Short-Term Investments | 2.51B | 2.55B | 4.33B | 4.80B | 4.25B | 2.00B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 252.76M | 244.34M | 471.07M | 408.24M | 221.41M | 214.95M |
| Stockholders Equity | 2.33B | 2.44B | 4.16B | 4.50B | 4.28B | 2.06B |
Cash Flow | ||||||
| Free Cash Flow | -1.84B | -1.84B | -1.94B | 543.01M | -1.72B | -546.92M |
| Operating Cash Flow | -1.84B | -1.84B | -1.94B | 543.73M | -1.70B | -544.59M |
| Investing Cash Flow | -5.33M | -5.33M | -10.96M | 345.00K | -14.70M | -2.36M |
| Financing Cash Flow | 61.58M | 61.58M | 1.48B | 0.00 | 3.98B | 1.53B |
Chordia Therapeutics Inc. Technical Analysis
Negative
108.00
Price Trends
77.18
Negative
101.43
Negative
108.94
Negative
Market Momentum
-0.75
Positive
39.13
Neutral
40.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Negative. The current price of 108 is above the 20-day moving average (MA) of 78.95, above the 50-day MA of 77.18, and below the 200-day MA of 108.94, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 39.13 is Neutral, neither overbought nor oversold. The STOCH value of 40.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:190A.
Chordia Therapeutics Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥45.01B | 13.47 | ― | 2.53% | 3.38% | 32.41% | |
69 Neutral | ¥523.53B | 16.25 | ― | 1.28% | 8.72% | 3.45% | |
66 Neutral | ¥53.17B | -84.07 | ― | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥5.89B | 49.80 | ― | 2.65% | 9.45% | ― | |
48 Neutral | ¥7.43B | -10.78 | ― | ― | -71.21% | -485.42% | |
42 Neutral | ¥5.72B | -3.59 | ― | ― | ― | 33.26% |
* General Sector Average
JP:190A
Chordia Therapeutics Inc.
72.00
-105.00
-59.32%
JP:2796
Pharmarise Holdings Corp.
500.00
13.11
2.69%
JP:3349
COSMOS Pharmaceutical Corporation
6,569.00
-2,365.16
-26.47%
JP:4890
Tsubota Laboratory Incorporated
290.00
-77.00
-20.98%
JP:4931
Shinnihonseiyaku Co., Ltd.
2,095.00
-290.46
-12.18%
JP:219A
Heartseed, Inc.
2,465.00
-1,020.00
-29.27%
Chordia Therapeutics Inc. Corporate Events
Chordia Wins Japan Orphan Drug Status for Lead AML Therapy rogocekib
Aug 25, 2026
Chordia Therapeutics has secured Orphan Drug Designation in Japan for its lead candidate rogocekib, a CLK inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia, following a similar designation previously granted by the U.S....
Chordia’s Lead Cancer Drug Rogocekib Wins Japan Orphan Drug Endorsement for AML
Jul 28, 2026
Chordia Therapeutics, a Fujisawa-based oncology-focused biopharmaceutical developer, is advancing a portfolio of targeted small-molecule therapies, led by rogocekib, a first-in-class CLK inhibitor in Phase 1/2 trials in the U.S. The company is als...
Chordia Therapeutics Wins AMED Grant for Advanced Cancer Research with Kyoto University
Jul 17, 2026
Chordia Therapeutics Inc. has secured a JPY 30 million grant under Japan’s “Research Project for Innovative Cancer Therapy Application,” administered by the Japan Agency for Medical Research and Development. The funding is tied t...
Chordia Therapeutics Narrows Nine-Month Loss But Stays Deep in Red
Jul 15, 2026
Chordia Therapeutics reported a non-consolidated operating loss of ¥1,070 million for the nine months ended May 31, 2026, narrowing from a ¥1,420 million loss a year earlier, with a net loss of ¥1,047 million translating to a basic ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.